Last edition
News about " John Kraus"
Otsuka's Voyxact Phase 3 Trial Shows Long-Term Kidney Protection in IgA Nephropathy
Otsuka's Voyxact delivered significant long-term kidney function stabilization and reduced the risk of kidney failure in the Phase 3 VISIONARY trial, strengthening its potential as a disease-modifying treatment for IgA nephropathy.
John Kraus | 04/07/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members